Inovio announces pricing of approximately $36 million underwritten offering of common stock and pre-funded warrants

Plymouth meeting, pa. , april 15, 2024 /prnewswire/ -- inovio pharmaceuticals, inc. (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case before underwriting discounts and commissions.
INO Ratings Summary
INO Quant Ranking